Streetbeat News

Products Services

LTRN

Lantern Pharma's stock is trading higher following the approval to expand its Harmonic clinical trial for non-small cell lung cancer in never-smokers into Japan and Taiwan.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:29 pm

HUGE

Celly Nutrition Corp. (Celly Nu) announces a partnership with BevSource for the launch of its dietary supplement, unbuzzd™, in the United States. This collaboration aims to support production and distribution, leveraging BevSource's experience with brands like Celsius. The launch is led by industry veterans Gerry David, John Duffy, and Kevin Harrington. Duffy highlights the partnership as a critical step towards introducing unbuzzd™ to the US and eventually North America.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:22 pm

MLEC

Shares of Moolec Science SA (NASDAQ:MLEC) surged after announcing USDA-APHIS approval for its genetically engineered soybean, Piggy Sooy, which produces animal meat protein. This marks a significant biotechnological milestone, as it's the first product of its kind to receive such approval, indicating it does not pose an increased plant pest risk. The company previously reported high levels of pork protein expression in Piggy Sooy seeds and has patented the technology.

Portfolio Pulse from Shivani Kumaresan

April 22, 2024 | 12:22 pm

EEIQ

EpicQuest Education Group International Ltd (EEIQ) announced that its EduGlobal College has received approval for two new co-op programs, significantly expanding its academic offerings. The PTIB-approved programs have tripled, and all academic programs have seen a 50% increase.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:18 pm

WAT

Waters Corporation (NYSE:WAT) has launched GTxResolve Premier SEC Columns, enhancing the development of gene-based therapeutics. These columns offer higher sensitivity, resolution, and throughput, reducing non-specific binding and mobile phase method development challenges. They are designed to accelerate the development of mRNA, lipid nanoparticle, and viral vector-based therapies by providing up to 50% increased resolution for critical components, supporting faster and more efficient drug development processes.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:15 pm

SATL

Satellogic Inc. (NASDAQ:SATL), a leader in Earth Observation data, has signed a letter of intent with O.N.E. Amazon to support the creation of the Internet of Forests, aimed at monitoring the Amazon rainforest. This partnership emphasizes the use of Satellogic's sub-meter resolution satellite technology for environmental preservation and will be highlighted by Satellogic's President at an event in Washington, D.C.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:15 pm

ENPH

Enphase Energy, Inc. (NASDAQ:ENPH) has announced a strategic partnership with Octopus Energy Group to deploy Enphase IQ8 Microinverters and IQ Battery 5P in the UK. This collaboration allows Octopus Energy's customers to integrate Enphase's solar and battery systems into their energy plans, enabling low-cost residential energy rates and the creation of virtual power plants through Octopus' Kraken platform. The partnership aims to reduce energy costs for consumers and support a greener grid by managing energy usage efficiently. Enphase's products come with industry-leading warranties and are designed to meet the latest UK grid connection requirements.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:14 pm

CRM

IHG

IHG Hotels & Resorts is standardizing on Salesforce's Loyalty Management to enhance its IHG One Rewards program. This collaboration aims to drive guest loyalty, offer personalized experiences, and achieve greater efficiencies by utilizing Salesforce's Einstein 1 Platform. This platform integrates CRM, AI, data, and trust, enabling IHG to provide tailored guest experiences and deepen connections with its guests. The move reflects the growing consumer demand for personalized services, with IHG leveraging Salesforce's technology to meet these expectations.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:13 pm

LTRN

Lantern Pharma has received approval to expand its Harmonic clinical trial for non-small cell lung cancer in never-smokers into Japan and Taiwan, with Dr. Yashushi Goto of the National Cancer Center of Japan as a lead investigator.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:13 pm

PFE

The European Commission has granted approval to Pfizer's EMBLAVEO, a β-lactam/β-lactamase inhibitor antibiotic combination, for treating serious infections in adults caused by multidrug-resistant Gram-negative bacteria. This marks the first approval of its kind in the European Union, specifically targeting infections with limited treatment options, including those caused by metallo-β-lactamase-producing bacteria. EMBLAVEO was expedited through the European Medicines Agency's accelerated assessment procedure, highlighting its significance for public health and therapeutic innovation.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:10 pm